Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The present and future of bispecific antibodies for cancer therapy
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …
applications that cannot be achieved using conventional IgG-based antibodies …
Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer
AN Shouse, KM LaPorte, TR Malek - Immunity, 2024 - cell.com
Summary Interleukin-2 (IL-2) is a critical cytokine for T cell peripheral tolerance and
immunity. Here, we review how IL-2 interaction with the high-affinity IL-2 receptor (IL-2R) …
immunity. Here, we review how IL-2 interaction with the high-affinity IL-2 receptor (IL-2R) …
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
IL2 signals pleiotropically on diverse cell types, some of which contribute to therapeutic
activity against tumors, whereas others drive undesired activity, such as immunosuppression …
activity against tumors, whereas others drive undesired activity, such as immunosuppression …
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Regulatory T cells (Tregs) expressing the transcription factor FoxP3 are essential for
maintaining immunological balance and are a significant component of the …
maintaining immunological balance and are a significant component of the …
[HTML][HTML] CD8-Targeted IL2 unleashes tumor-specific immunity in Human Cancer tissue by reviving the dysfunctional T-cell Pool
Tumor-specific CD8+ T cells are key effectors of antitumor immunity but are often rendered
dysfunctional in the tumor microenvironment. Immune-checkpoint blockade can restore …
dysfunctional in the tumor microenvironment. Immune-checkpoint blockade can restore …
Harnessing CD8 T cell responses using PD-1–IL-2 combination therapy
There is considerable interest in develo** more effective programmed cell death (PD)-1
combination therapies against cancer. One major obstacle to these efforts is a dysfunctional …
combination therapies against cancer. One major obstacle to these efforts is a dysfunctional …
Adoptive cell therapy for solid tumors: current status in melanoma and next-generation therapies
J Haanen, C Los, GQ Phan… - American Society of …, 2024 - ascopubs.org
With the FDA approval of lifileucel, a cell product consisting of unmodified but in vitro
expanded tumor-infiltrating lymphocytes, in short TIL, for the treatment of patients with …
expanded tumor-infiltrating lymphocytes, in short TIL, for the treatment of patients with …
IL-2 based cancer immunotherapies: An evolving paradigm
Discovered over 4 decades ago in the supernatants of activated T cells, interleukin-2 (IL-2)
is a potent pleiotropic cytokine involved in the regulation of immune responses. It is required …
is a potent pleiotropic cytokine involved in the regulation of immune responses. It is required …
Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Immunotherapy has limited efficacy in glioblastoma (GBM) due to the blood–brain barrier
and the immunosuppressed or “cold” tumor microenvironment (TME) of GBM, which is …
and the immunosuppressed or “cold” tumor microenvironment (TME) of GBM, which is …
RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine–Induced Antitumor T-cell Immunity
Abstract Interleukin 2 (IL-2) is a crucial cytokine in T-cell immunity, with a promising potential
in cancer vaccines. However, therapeutic application of IL-2 is hampered by its short half-life …
in cancer vaccines. However, therapeutic application of IL-2 is hampered by its short half-life …